Welcome to our dedicated page for Volitionrx SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
VolitionRx’s SEC filings are packed with pages of nucleosomics data, clinical-trial updates and financing details that can overwhelm even seasoned analysts. Missing a single Form 8-K about a new licensing deal or overlooking insider buying in a Form 4 could distort your view of this diagnostics innovator. Stock Titan’s AI turns those dense disclosures into clear takeaways, so you can focus on the science and the numbers that move VNRX’s valuation.
Our platform ingests every submission to EDGAR the instant it drops and produces plain-English highlights, red-flag alerts and side-by-side comparisons. Whether you’re searching for “VolitionRx quarterly earnings report 10-Q filing” or need “VolitionRx insider trading Form 4 transactions” before market open, we have you covered. Key documents are mapped to the insights they contain:
- 10-K / annual report — cash-burn trends, patent status, and pipeline milestones in one “VolitionRx annual report 10-K simplified” summary.
- 10-Q / quarterly earnings — segment spending, licensing revenue and trial enrollment metrics with concise “VolitionRx earnings report filing analysis”.
- 8-K — real-time alerts on material events; think “VolitionRx 8-K material events explained” minutes after filing.
- Form 4 — “VolitionRx Form 4 insider transactions real-time” so you can track executive stock moves the moment they file.
- DEF 14A proxy — drill into “VolitionRx proxy statement executive compensation” without digging through appendices.
Use Stock Titan’s AI-powered summaries, red-flag detectors and historical sidebars to understand R&D spend, dilution risk and partnership economics—“understanding VolitionRx SEC documents with AI” has never been easier. Schedule custom alerts, export tables for models and compare “VolitionRx executive stock transactions Form 4” against peer trends, all from one screen.
Transaction summary: Ann-Louise Batchelor, Group Chief Marketing Officer, filed a Form 4 for VolitionRx Ltd (VNRX) reporting activity dated 08/01/2025.
Details: The filing states 18,341 restricted stock units were settled in lieu of cash compensation and that 8,620 shares were retained by VolitionRx for cancellation to satisfy the reporting person’s tax withholding obligations. The filing explicitly states no shares were sold. Following the reported transaction, Batchelor beneficially owns 132,486 shares directly and 29,406 shares indirectly (by spouse). The table shows a price of $0.64. Form signed 08/05/2025.
VolitionRx Ltd. (VNRX) – Form 4 filing
Chief Commercial Officer Gael Forterre reported a single Code F transaction on 1 Aug 2025, reflecting shares surrendered to the company to cover taxes upon settlement of 6,690 restricted stock units received in lieu of cash compensation. 2,766 common shares were withheld at an implied price of $0.64 and therefore cancelled; no open-market sale occurred.
Following the withholding, Forterre’s holdings stand at 156,700 directly-owned shares. He also reports 5,000 shares held indirectly by his spouse and 32,500 shares managed through Armorica Partners, LLC, over which he exercises voting and dispositive control. The filing represents routine administrative tax withholding and does not signal a change in insider ownership intent or corporate outlook.
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
